475 related articles for article (PubMed ID: 33397585)
1. Mesenchymal stromal cells to fight SARS-CoV-2: Taking advantage of a pleiotropic therapy.
Barros I; Silva A; de Almeida LP; Miranda CO
Cytokine Growth Factor Rev; 2021 Apr; 58():114-133. PubMed ID: 33397585
[TBL] [Abstract][Full Text] [Related]
2. Mesenchymal stem cell therapy for acute respiratory distress syndrome: from basic to clinics.
Qin H; Zhao A
Protein Cell; 2020 Oct; 11(10):707-722. PubMed ID: 32519302
[TBL] [Abstract][Full Text] [Related]
3. Mesenchymal stromal cells for acute respiratory distress syndrome (ARDS), sepsis, and COVID-19 infection: optimizing the therapeutic potential.
Gorman E; Millar J; McAuley D; O'Kane C
Expert Rev Respir Med; 2021 Mar; 15(3):301-324. PubMed ID: 33172313
[No Abstract] [Full Text] [Related]
4. Double-blind, randomized, controlled, trial to assess the efficacy of allogenic mesenchymal stromal cells in patients with acute respiratory distress syndrome due to COVID-19 (COVID-AT): A structured summary of a study protocol for a randomised controlled trial.
Payares-Herrera C; Martínez-Muñoz ME; Vallhonrat IL; de Molina RM; Torres MP; Trisan A; de Diego IS; Alonso R; Zafra R; Donaire T; Sánchez R; Rubio JJ; Duarte Palomino RF; Solá CA
Trials; 2021 Jan; 22(1):9. PubMed ID: 33407777
[TBL] [Abstract][Full Text] [Related]
5. Current Status of Cell-Based Therapies for COVID-19: Evidence From Mesenchymal Stromal Cells in Sepsis and ARDS.
Xu Z; Huang Y; Zhou J; Deng X; He W; Liu X; Li Y; Zhong N; Sang L
Front Immunol; 2021; 12():738697. PubMed ID: 34659231
[TBL] [Abstract][Full Text] [Related]
6. Safety and Effectiveness of Intravascular Mesenchymal Stem Cells to Treat Organ Failure and Possible Application in COVID-19 Complications.
Atluri S; Manocha V; Boddu N; Bhati S; Syed Z; Diwan S; Manchikanti L
Pain Physician; 2020 Aug; 23(4S):S391-S420. PubMed ID: 32942796
[TBL] [Abstract][Full Text] [Related]
7. The rationale of using mesenchymal stem cells in patients with COVID-19-related acute respiratory distress syndrome: What to expect.
Can A; Coskun H
Stem Cells Transl Med; 2020 Nov; 9(11):1287-1302. PubMed ID: 32779878
[TBL] [Abstract][Full Text] [Related]
8. Mesenchymal Stromal Cells in Viral Infections: Implications for COVID-19.
Rocha JLM; de Oliveira WCF; Noronha NC; Dos Santos NCD; Covas DT; Picanço-Castro V; Swiech K; Malmegrim KCR
Stem Cell Rev Rep; 2021 Feb; 17(1):71-93. PubMed ID: 32895900
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of MSC in Patients with Severe COVID-19: Analysis of the Literature and a Case Study.
Grumet M; Sherman J; Dorf BS
Stem Cells Transl Med; 2022 Nov; 11(11):1103-1112. PubMed ID: 36181766
[TBL] [Abstract][Full Text] [Related]
10. Review of Trials Currently Testing Stem Cells for Treatment of Respiratory Diseases: Facts Known to Date and Possible Applications to COVID-19.
Majolo F; da Silva GL; Vieira L; Timmers LFSM; Laufer S; Goettert MI
Stem Cell Rev Rep; 2021 Feb; 17(1):44-55. PubMed ID: 32827081
[TBL] [Abstract][Full Text] [Related]
11. Potential application of mesenchymal stem cells and their exosomes in lung injury: an emerging therapeutic option for COVID-19 patients.
Al-Khawaga S; Abdelalim EM
Stem Cell Res Ther; 2020 Oct; 11(1):437. PubMed ID: 33059757
[TBL] [Abstract][Full Text] [Related]
12. MSC Therapies for COVID-19: Importance of Patient Coagulopathy, Thromboprophylaxis, Cell Product Quality and Mode of Delivery for Treatment Safety and Efficacy.
Moll G; Drzeniek N; Kamhieh-Milz J; Geissler S; Volk HD; Reinke P
Front Immunol; 2020; 11():1091. PubMed ID: 32574263
[TBL] [Abstract][Full Text] [Related]
13. Investigational Use of Mesenchymal Stem/Stromal Cells and Their Secretome as Add-On Therapy in Severe Respiratory Virus Infections: Challenges and Perspectives.
Mattoli S; Schmidt M
Adv Ther; 2023 Jun; 40(6):2626-2692. PubMed ID: 37069355
[TBL] [Abstract][Full Text] [Related]
14. Heterogeneous expression of ACE2 and TMPRRS2 in mesenchymal stromal cells.
Generali M; Kehl D; Wanner D; Okoniewski MJ; Hoerstrup SP; Cinelli P
J Cell Mol Med; 2022 Jan; 26(1):228-234. PubMed ID: 34821008
[TBL] [Abstract][Full Text] [Related]
15. Mesenchymal stromal/stem cells (MSCs) and MSC-derived extracellular vesicles in COVID-19-induced ARDS: Mechanisms of action, research progress, challenges, and opportunities.
Moradinasab S; Pourbagheri-Sigaroodi A; Zafari P; Ghaffari SH; Bashash D
Int Immunopharmacol; 2021 Aug; 97():107694. PubMed ID: 33932694
[TBL] [Abstract][Full Text] [Related]
16. Mesenchymal stem cells: a new front emerges in coronavirus disease 2019 treatment.
Raza SS; Khan MA
Cytotherapy; 2022 Aug; 24(8):755-766. PubMed ID: 35880307
[TBL] [Abstract][Full Text] [Related]
17. Systematic review and meta-analysis of cell therapy for COVID-19: global clinical trial landscape, published safety/efficacy outcomes, cell product manufacturing and clinical delivery.
Couto PS; Al-Arawe N; Filgueiras IS; Fonseca DLM; Hinterseher I; Catar RA; Chinnadurai R; Bersenev A; Cabral-Marques O; Moll G; Verter F
Front Immunol; 2023; 14():1200180. PubMed ID: 37415976
[TBL] [Abstract][Full Text] [Related]
18. Mesenchymal stem/stromal cell therapy for COVID-19 pneumonia: potential mechanisms, current clinical evidence, and future perspectives.
Yao W; Shi L; Zhang Y; Dong H; Zhang Y
Stem Cell Res Ther; 2022 Mar; 13(1):124. PubMed ID: 35321737
[TBL] [Abstract][Full Text] [Related]
19. Expediting Molecular Translational Approach of Mesenchymal Stem Cells in COVID-19 Treatment.
Balaji Easwaran V; Satarker S; V Gujaran T; John J; Veedu AP; George KT; Purayil DK; Beegum F; Mathew A; Vibhavari R; Chaudhari SS; Pai KSR
Curr Stem Cell Res Ther; 2023; 18(5):653-675. PubMed ID: 36424799
[TBL] [Abstract][Full Text] [Related]
20. Immunomodulation of Mesenchymal Stem Cells in Acute Lung Injury: From Preclinical Animal Models to Treatment of Severe COVID-19.
Li JP; Wu KH; Chao WR; Lee YJ; Yang SF; Chao YH
Int J Mol Sci; 2022 Jul; 23(15):. PubMed ID: 35897770
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
